Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Outlook Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Active clinical diagnosis and OCT confirmation of one of the following retinal disorders: exudative age-related macular degeneration (AMD), diabetic macular edema (DME), or branch retinal vein occlusion (BRVO) and, in the opinion of the Investigator, requires treatment with an anti-VEGF therapy
You may not be if
Previous use of approved anti-VEGF or Avastin® within 4 weeks preceding randomization
Previous use of Beovu®
Macular edema due to something other than exudative AMD, DME or BRVO, in the study eye
History of inadequate response to previous intravitreal anti-VEGF therapy
History of any intraocular or periocular corticosteroid injection or implant, in the study eye
Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization
Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss during the study period
Active intraocular inflammation in the study eye
Current vitreous hemorrhage in the study eye
Polypoidal choroidal vasculopathy (PCV) in the study eye
History of idiopathic, infectious or autoimmune-associated uveitis in either eye
Current ocular or periocular infection, such as conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
Premenopausal women not using adequate contraception
Current treatment for active systemic infection
Known allergy to any component of the study drug , not amenable to treatment
